Since CD137 ligand crosslinking enhances proliferation of preactivated B cells, we tested this activity in B cell lines [22], [28].
Various retinoids were tested for their activity in the adhesion test, and this activity was found to correlate well with their biological activity in maintaining the expression of normal epithelial differentiation in other systems.
To test whether this activity is a selective antiangiogenic or a result of a direct cytotoxic activity, the anti-PLF proliferative test at 100 μg/mL was performed.
The safety implications of blocking the human cardiac Na+ channel (hNav1.5) make it prudent to test for this activity early in the drug discovery process and design-out any potential liability.
In order to test if this activity could be also seen in cell free extracts we analysed the cell free extracts of the CEN.PK strains which were not modified or expressed the PAD1 gene.
To test for this activity, Galβ1,3GalNAcα1 pNP was incubated with various 1-alkanols in the presence of EngCP, EngEF, EngPA, EngSP, and EngAL.
To test this hypothesis, activity of cathepsin B in cytoplasmic extracts of untreated and treated RPMI 8226 cells was determined.
In order to test this, the activity of the NFAT-luciferase promoter construct induced by treatment with PROK1 was measured in cells infected with empty or RCAN1-4 adenovirus.
Structures from the SDFile with unknown activity that end up in clusters that contain structures with known activity have a high probability to show the same biological effects, thus are potential candidates for testing against this activity.
Incompatibility reactions have been identified essentially in all species that were tested for this activity.
